BC3195 plus Keytruda for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial is testing a new drug called BC3195 combined with pembrolizumab (Keytruda) for people with advanced solid tumors that haven't responded to other treatments. It aims to see if the combination can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need to have a type of advanced cancer (like lung, breast, head and neck, or others) that has stopped responding to standard treatments.
- You should be in generally good health, able to take care of yourself (ECOG score 0 or 1).
- You must have at least one tumor that can be measured on a scan.
- You need to have adequate liver, kidney, and bone marrow function, as shown by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BC3195 in people with advanced or metastatic solid tumors that have not responded to or cannot tolerate standard treatments. It aims to see if the drug is safe and effective for cancers that express a specific marker called CDH3.
This trial is testing two new drugs (DB-1311 with BNT327 or DB-1305) in people with certain advanced or metastatic solid tumors that have not responded to prior treatments. It aims to see if the combination shrinks tumors or slows cancer growth.
This trial tests a new medicine called BNT326, alone or with another drug BNT327, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and might help shrink tumors.
This trial tests a new drug called BNT3212, either alone or combined with BNT327, in people with advanced solid tumors that have not gotten better with standard treatments. The goal is to find safe doses and see if the drugs can shrink tumors or slow their growth.
This trial studies TU2218 taken with Keytruda (pembrolizumab) in adults with advanced solid cancers that have limited treatment options. The goal is to see if the combination can shrink tumors and is safe enough to keep using.
This trial tests a new drug called BNT317 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if BNT317 is safe and if it can help shrink tumors.
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.